Knowledge Base:  
BLOG LIST >
An interview with key opinion leader Dr. Ito Puruhito
Last Updated: 08/31/2017


May 22, 2017

D’OXYVA® technology is a fast, reliable and effective approach for boosting circulation and promoting wellness for patients with diabetes and varicose veins. An interview with key opinion leader Dr. Ito Puruhito

Effective O2 and nutrient distribution from our lungs and guts to our organ tissues depends on micro-circulation. Microcirculation is where the vascular system allows the intravascular volume to interact with the extravascular space to deliver O2 and nutrients and in exchange pick up metabolic waste. When these physical processes are interrupted, our body becomes stressed.


Physiologic stress is useful and essential for our survival. For example, when we are sick it plays a crucial role in recruiting the immune cell protagonists to help us overcome infections and sickness. But when the stress transforms from a transitory state to a permanent state, our body loses the capacity to self-heal and achieves homeostasis over time. D’OXYVA® technology and its revolutionary CO2 transdermal delivery allow our body to regain proper micro-circulation blood flow to our organs.


One of the most common public health problems related with poor microcirculation is diabetic foot ulcers. Diabetic foot ulcers are a healthcare problem that affects more than 6.5 million patients in the USA alone. It is expected that 15% of this population are at risk of developing diabetic ulcers. Further epidemiological studies have identified that almost 25% of diabetic patients are at risk of lower extremity amputation and foot ulcers preceded 85% of all amputations.


Diabetic patients with concomitant foot ulcers represent a perpatient annual health-care cost that ranges between $12,000 and $17,000. Nationally the USA spends $13 billion in healthcare management of diabetic foot ulcers complication in addition to the expenses associated with diabetes itself.


To help our community to better understand the disease and the new proposed technology for improving diabetic patients’ quality of life, we interviewed Prof. Ito Puruhito, a world renowned cardio-thoracic surgeon based in Indonesia who has shared his knowledge at several top universities including Harvard. Prof. Puruhito has focused his research and efforts on better understanding micro-circulation, particularly in the wound healing process.


In our interview, Prof. Puruhito pointed out the importance of microcirculation health literacy among diabetic patients. He stated: “The better the circulation, the better the body can function in general. Micro-circulation delivers blood and oxygen directly to tissue, and when it is impaired, virtually every bodily function suffers.” Improving micro-circulation—especially in ulcers developed in diabetic patients—leads to improved treatment response, shorter healing time, and ulcer prevention. In other words, it will improve patient quality of life and may prevent extremity amputation.micro-circulation health literacy among diabetic patients. He stated: “The better the circulation, the better the body can function in general. Micro-circulation delivers blood and oxygen directly to tissue, and when it is impaired, virtually every bodily function suffers.” Improving micro-circulation—especially in ulcers developed in diabetic patients—leads to improved treatment response, shorter healing time, and ulcer prevention. In other words, it will improve patient quality of life and may prevent extremity amputation.


Prof. Puruhito has dedicated the last 50 years to researching how to improve microcirculation in his patients. During this time he tested several strategies and
products intended to improve microcirculation and found D’OXYVA® technology to be the most efficient medical device.


Prof. Puruhito stated: “The D’OXYVA® technology caught my attention because of its remarkable ability to deliver such a high concentration of CO2 directly to the bloodstream.” He also said: “The ability to interact directly with dermal capillary and cellular receptors near the skin gives it the ability to produce the desired systemic effects, which is critical for improving micro-circulation and wound healing.”


Prof. Puruhito is part of the D’OXYVA® independent researcher team. He has been studying D’OXYVA®’s positive impact on his patients and has documented a remarkable success rate with difficult-to-treat wounds and diabetic ulcers. Also, his preliminary findings indicate clear improvements in health care indicators such as peripheral O2 concentration and perfusion indexes among his patients (scientific article pending for publication). Shortly after he recognized D’OXYVA® ’s healthcare benefits for general body health, he started to use D’OXYVA® on a daily basis and said: “As a researcher, it is one thing to observe results in your patients, but another to experience them in your body. With D’OXYVA® ’s transdermal technology, I had both!”


D’OXYVA® ’s consistent positive impact in improving microcirculation and health quality is leading to new treatment options for other pathologies such as varicose veins and cellulite, among others. We are confident that D’OXYVA® technology and effective transdermal delivery of CO2 will continue to prove its capacity to help the body improve its microcirculation and its capacity to self-heal and achieve homeostasis.


Bibliography

Chandan K. Sen, P. G. (2003, Nov–Dec). Human Skin Wounds: A Major and Snowballing Threat to Public Health and the Economy. Wound Repair Regen., 17(6), 763–771.

Doupis, K. A. (2012). Management of Diabetic foot ulcer . Diabetes Ther.

McCall, B. (2014, march 13). Medscape. Retrieved from Medscape/News & Perspective .


Special thanks to Prof. Puruhito for allowing us to perform the interview at the International Wound Care and Biotherapy Conference in Kuala Lumpur (2015). Dr. Ito Puruhito is a cardiothoracic surgeon with more than 50 years of experience and Professor of Surgery at Airlangga University Medical School in Surabaya, Indonesia. This article was published thanks to: “Circularity Healthcare” – D’OXYVA® , interviewer: Dr. Paul Kirkitelos.



Was this article helpful?

Comments: